Claims
- 1. A combination to enable enhanced penetration of cancerous cells and enable reduced dosage of chemotherapeutic agents to mammalian patients comprising:
an HMG-CoA reductase inhibitor, a selective COX-2 inhibitor, and a chemotherapeutic agent.
- 2. The combination according to claim 1, further comprising:
cystine.
- 3. The combination according to claim 2, further comprising:
lipoic acid.
- 4. A combination to enable enhanced penetration of cancerous cells and enable reduced dosage of chemotherapeutic agents to mammalian patients comprising:
an HMG-CoA reductase inhibitor, a selective COX-2 inhibitor, a chemotherapeutic agent, and cystine.
- 5. The combination according to claim 4, further comprising:
lipoic acid.
- 6. A combination to enable enhanced penetration of cancerous cells and enable reduced dosage of chemotherapeutic agents to mammalian patients comprising:
a selective COX-2 inhibitor, and a chemotherapeutic agent.
- 7. The combination according to claim 6, further comprising:
cystine.
- 8. The combination according to claim 7, further comprising:
lipoic acid.
- 9. A combination to enable enhanced penetration of cancerous cells and enable reduced dosage of chemotherapeutic agents to mammalian patients comprising:
a selective COX-2 inhibitor, a chemotherapeutic agent, and cystine.
- 10. The combination according to claim 9, further comprising:
lipoic acid.
- 11. A method of enhancing penetration of cancerous cells and enabling reduced dosage of chemotherapeutic agents to mammalian patients comprising the following steps:
administering an HMG-CoA reductase inhibitor, a selective COX-2 inhibitor, and a chemotherapeutic agent.
- 12. The method according to claim 11, further comprising the following step:
timing the administration of said at least one chemotherapeutic agent with the administration of said HMG-CoA reductase inhibitor and said selective COX-2 inhibitor so that the therapeutic effect of said at least one chemotherapeutic agent corresponds to maximum concentration of said HMG-CoA reductase inhibitor and said selective COX-2 inhibitor.
- 13. The method according to claim 12, further comprising the following step:
administering cystine to said patient.
- 14. The method according to claim 13, further comprising the following step:
administering lipoic acid.
- 15. The method according to claim 12, further comprising the following step:
timing the administration of said at least one chemotherapeutic agent with the administration of said HMG-CoA reductase inhibitor and said selective COX-2 inhibitor so that the therapeutic effect of said at least one chemotherapeutic agent corresponds to maximum therapeutic effect of said HMG-CoA reductase inhibitor and said selective COX-2 inhibitor.
- 16. The method according to claim 15, further comprising the following step:
administering cystine to said patient.
- 17. The method according to claim 16, further comprising the following step:
administering lipoic acid.
- 18. A method of enhancing penetration of cancerous cells and enabling reduced dosage of chemotherapeutic agents to mammalian patients comprising the following steps:
administering an HMG-CoA reductase inhibitor, a selective COX-2 inhibitor, cystine and a chemotherapeutic agent.
- 19. The method according to claim 18, further comprising the following step:
timing the administration of said at least one chemotherapeutic agent with the administration of said HMG-CoA reductase inhibitor and said selective COX-2 inhibitor so that the therapeutic effect of said at least one chemotherapeutic agent corresponds to maximum concentration of said HMG-CoA reductase inhibitor and said selective COX-2 inhibitor.
- 20. The method according to claim 19, further comprising the following step:
administering lipoic acid.
- 21. The method according to claim 18, further comprising the following step:
timing the administration of said at least one chemotherapeutic agent with the administration of said HMG-CoA reductase inhibitor and said selective COX-2 inhibitor so that the therapeutic effect of said at least one chemotherapeutic agent corresponds to maximum therapeutic effect of said HMG-CoA reductase inhibitor and said selective COX-2 inhibitor.
- 22. The method according to claim 21, further comprising the following step:
administering lipoic acid.
- 23. A method of enhancing penetration of cancerous cells and enabling reduced dosage of chemotherapeutic agents to mammalian patients comprising the following steps:
administering a selective COX-2 inhibitor, and a chemotherapeutic agent.
- 24. The method according to claim 23, further comprising the following step:
timing the administration of said at least one chemotherapeutic agent with the administration of said selective COX-2 inhibitor so that the therapeutic effect of said at least one chemotherapeutic agent corresponds to maximum concentration of said selective COX-2 inhibitor.
- 25. The method according to claim 24, further comprising the following step:
administering cystine to said patient.
- 26. The method according to claim 25, further comprising the following step:
administering lipoic acid.
- 27. The method according to claim 23, further comprising the following step:
timing the administration of said at least one chemotherapeutic agent with the administration of said selective COX-2 inhibitor so that the therapeutic effect of said at least one chemotherapeutic agent corresponds to maximum therapeutic effect of said selective COX-2 inhibitor.
- 28. The method according to claim 27, further comprising the following step:
administering cystine to said patient.
- 29. The method according to claim 28, further comprising the following step:
administering lipoic acid.
- 30. A method of enhancing penetration of cancerous cells and enabling reduced dosage of chemotherapeutic agents to mammalian patients comprising the following steps:
administering a selective COX-2 inhibitor, a chemotherapeutic agent and cystine.
- 31. The method according to claim 30, further comprising the following step:
timing the administration of said at least one chemotherapeutic agent with the administration of said selective COX-2 inhibitor so that the therapeutic effect of said at least one chemotherapeutic agent corresponds to maximum concentration of said selective COX-2 inhibitor.
- 32. The method according to claim 30, further comprising the following step:
timing the administration of said at least one chemotherapeutic agent with the administration of said selective COX-2 inhibitor so that the therapeutic effect of said at least one chemotherapeutic agent corresponds to maximum therapeutic effect of said selective COX-2 inhibitor.
Priority Claims (2)
Number |
Date |
Country |
Kind |
09912703 |
Jul 2001 |
US |
|
09997490 |
Nov 2001 |
US |
|
CONTINUATION DATA
[0001] For purposes of priority and continuation, this is a continuation-in-part of Provisional Application No. 60/264,512 filed in the United States of America on Jan. 26, 2001 entitled “A Composition and Method of Sustaining Chemotherapeutic Effect while Reducing Dose of Chemotherapeutic Agent preferably Using Selective Cox-2 Inhibitor and HMG-CoA Reductase Inhibitor” and Provisional Application No. 60/264,511 entitled “A Combination and Method of Treating of Cancer Utilizing an additional COX-2 Inhibitor Etoricoxib and a 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) Inhibitor and Cystine to Enhance Glutathione Function” also filed in the United States of America on Jan. 26, 2001 . It is also a continuation-in-part of provisional Application No. 60/307,689 and Utility Application Ser. No 09/912,703 both filed Jul. 25, 2001, and PCT US01/31328 entitled “A Combination and Method of Treatment of Cancer Utilizing A COX-2 Inhibitor etoricoxib and a 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitor” and a provisional application and Utility Application filed in the U.S. Nov. 17, 2001 No. 09/997,490, and a provisional application filed this day of this name, which provisional applications and utility application and other application(s) are incorporated by reference and priority claimed from them.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US02/02478 |
1/26/2002 |
WO |
|